C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the next stage in its partnership with C2i Genomics, a cancer intelligence company.

“Expanding our partnership with C2i Genomics’ and our IntegraGen lab in France, C2inform testing is now available for patients in the EU over the age of 18 with solid organ cancers. The lab uses C2inform, the first CE-IVDD marked software-as-a-medical-device molecular residual disease (MRD) test. Clinicians can order the C2inform test through our OncoShare platform,” said Jean-Pol Detiffe, Founder, Chief Strategy & Innovation Officer at OncoDNA.

The C2inform test applies whole-genome sequencing and C2i’s state-of-the-art cancer data analysis to a 4 mL blood sample to support the rapid and accurate detection of minimal residual disease (MRD)o monitor disease progression, evaluate therapeutic efficacy and detect cancer recurrence. The test allows for informed and timely personalized treatment decisions for cancer patients across the EU.

“As we continue to pave the way for precision medicine in the fight against cancer, we are proud to enter the next stage in our partnership with OncoDNA,” said Ezra Sofer, CEO and co-founder of C2i Genomics. “This launch of our C2inform test in Europe is a testament to our commitment to improving patient outcomes through innovative and personalized cancer diagnostics and our goal to have our test available for cancer patients in the clinic at an affordable price.”

The timely assessment of MRD enables:

C2inform has proven to better serve as a prognostic biomarker to guide the course of treatment toward either an organ-sparing watch-and-wait protocol or surgical resection.

Additionally, C2i Genomics is excited to strengthen the partnership with OncoDNA for a notable clinical trial that is being conducted by a leading European cancer research institution in partnership with a prominent pharmaceutical industry leader.

This strategic alliance will leverage C2i Genomics’ MRD solution alongside OncoDNA’s essential lab management and sample processing expertise, eliminating the need to develop a patient-specific assay, enabling high-performance, personalized monitoring and rapid turnaround across multiple solid cancers with reduced operational complexity.

Discover more about MRD solution

About C2i Genomics: Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 3-4mL blood) and offers ultra-sensitive whole-genome sequencing cancer detection and monitoring. With headquarters in NYC, CLIA lab in Cambridge MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high-precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. C2i was named to the 2021 CB Insights Digital 150 list and awarded the 2022 North American Digital Cancer Monitoring Platform Technology Innovation Leadership Award by Frost & Sullivan. For more information, please visit www.c2i-genomics.com.